Hansa Biopharma - Directed Share Issue of SEK 372 million
-
Hansa Biopharma AB: Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)
"Priset för de Nya Aktierna är 29,12 SEK per Ny Aktie, motsvarande stängningspriset av Hansas aktier på Nasdaq Stockholm den 11 april 2024."
-
Hansa Biopharma stärker kassan genom riktad nyemission på 372 miljoner kronor (Finwire)
"Bland investerarna som tecknat aktier finns Braidwell, Redmile Group, Fjärde AP-fonden, Sphera Healthcare, Woodline Partners, en entitet som förvaltas av Heights Capital Ireland och Maven Investment Partners."
...
Hansa Biopharma har framgångsrikt genomfört en riktad nyemission om 372 MSEK (~ 34,6 MUSD)
https://mb.cision.com/Main/1219/3960623/2727973.pdf
(Cision) -
Super-super nyhed - så er finansieringen på den mellemlange bane på plads. Frygtede lidt at vi skulle ud i en kæmpe udvanding à la Xbrane. Spændende at se om shorterne holder fast i deres positioner eller vælger et exit nu da finansieringen er på plads.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind